A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry's disease and mucopolysaccharidosis type 1.

Health technology assessment (Winchester, England)

Volumn 10, Issue 20, 2006, Pages

  Connock, M ^a   Juarez Garcia, A ^b   Frew, E ^b   Mans, A ^b   Dretzke, J ^b   Fry Smith, A ^b   Moore, D ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE; LEVO IDURONIDASE;

ADULT; COST BENEFIT ANALYSIS; ENZYMOLOGY; FABRY DISEASE; FEMALE; HUMAN; MALE; MIDDLE AGED; MUCOPOLYSACCHARIDOSIS; NATIONAL HEALTH SERVICE; PATHOPHYSIOLOGY; REVIEW; TREATMENT OUTCOME; UNITED KINGDOM;

ADULT; ALPHA-GALACTOSIDASE; COST-BENEFIT ANALYSIS; FABRY DISEASE; FEMALE; GREAT BRITAIN; HUMANS; IDURONIDASE; MALE; MIDDLE AGED; MUCOPOLYSACCHARIDOSES; STATE MEDICINE; TREATMENT OUTCOME;

EID: 84886943017     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta10200     Document Type: Review

References (177)